Older MRD vs. younger MUD in patients older than 50 years with AML in remission using post-transplant cyclophosphamide

An increasing number of older patients with acute myeloid leukemia (AML) are offered an allogeneic hematopoietic stem cell transplantation (allo-HSCT). Normally, older patients have older matched related donors (MRD). Matched unrelated donors (MUD) are an important alternative, but it remains unclea...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Leukemia 2024-09, Vol.38 (9), p.2016-2022
Hauptverfasser: Piemontese, Simona, Labopin, Myriam, Choi, Goda, Broers, Annoek E. C., Peccatori, Jacopo, Meijer, Ellen, Van Gorkom, Gwendolyn, Rovira, Montserrat, Pascual Cascon, Maria Jesús, Sica, Simona, Vydra, Jan, Kulagin, Alexander, Spyridonidis, Alexandros, Nagler, Arnon, Bazarbachi, Ali, Savani, Bipin, Brissot, Eolia, Sanz, Jaime, Mohty, Mohamad, Ciceri, Fabio
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:An increasing number of older patients with acute myeloid leukemia (AML) are offered an allogeneic hematopoietic stem cell transplantation (allo-HSCT). Normally, older patients have older matched related donors (MRD). Matched unrelated donors (MUD) are an important alternative, but it remains unclear whether a younger MUD is associated with better outcomes, especially in the context of post-transplant cyclophosphamide (PTCy). We compared outcomes of patients older than 50 years with AML in first complete remission (CR1) and receiving a first HSCT from a 10/10 MUD aged younger than 40 years to those receiving a graft from a MRD aged older than 50 years, using PTCy and with well-known transplant conditioning intensity (TCI) score. A total of 345 consecutive patients were included and classified according to TCI score as low, intermediate, or high. On multivariable analysis in the TCI-intermediate/high group, MUD was associated with better graft-versus-host disease-free, relapse-free survival, lower non-relapse mortality and lower relapse incidence. For patients receiving a TCI-low regimen, outcomes are independent on the type of donor. In patients with AML in CR1, older than 50 years and receiving a TCI-intermediate/high conditioning regimen using PTCy, a MUD younger than 40 years is preferable over a MRD older than 50 years.
ISSN:0887-6924
1476-5551
1476-5551
DOI:10.1038/s41375-024-02359-8